Stoke Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025

Published: 2025-05-13 07:00:00 ET STOK

Published on 05/13/2025 at 07:00, updated on 05/13/2025 at 08:50

Stoke Therapeutics, Inc. reported earnings results for the first quarter ended March 31, 2025. For the first quarter, the company reported sales was USD 158.57 million compared to USD 4.22 million a year ago. Net income was USD 112.88 million compared to net loss of USD 26.37 million a year ago.

Basic earnings per share from continuing operations was USD 1.95 compared to basic loss per share from continuing operations of USD 0.57 a year ago. Diluted earnings per share from continuing operations was USD 1.9 compared to diluted loss per share from continuing operations of USD 0.57 a year ago.